BRPI0820733A2 - Processo para a preparação de macrociclo - Google Patents

Processo para a preparação de macrociclo

Info

Publication number
BRPI0820733A2
BRPI0820733A2 BRPI0820733-0A BRPI0820733A BRPI0820733A2 BR PI0820733 A2 BRPI0820733 A2 BR PI0820733A2 BR PI0820733 A BRPI0820733 A BR PI0820733A BR PI0820733 A2 BRPI0820733 A2 BR PI0820733A2
Authority
BR
Brazil
Prior art keywords
macrocycle
preparation
macrocycle preparation
Prior art date
Application number
BRPI0820733-0A
Other languages
English (en)
Inventor
Stefan Hildbrand
Kurt Puentener
Michelangelo Scalone
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0820733A2 publication Critical patent/BRPI0820733A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BRPI0820733-0A 2007-12-21 2008-12-11 Processo para a preparação de macrociclo BRPI0820733A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07150287 2007-12-21
PCT/EP2008/067309 WO2009080542A1 (en) 2007-12-21 2008-12-11 Process for the preparation of a macrocycle

Publications (1)

Publication Number Publication Date
BRPI0820733A2 true BRPI0820733A2 (pt) 2015-06-16

Family

ID=40456983

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820733-0A BRPI0820733A2 (pt) 2007-12-21 2008-12-11 Processo para a preparação de macrociclo

Country Status (12)

Country Link
US (1) US7910728B2 (pt)
EP (1) EP2225249B1 (pt)
JP (1) JP5439384B2 (pt)
KR (1) KR101629523B1 (pt)
CN (1) CN101903391B (pt)
AU (1) AU2008340430B2 (pt)
BR (1) BRPI0820733A2 (pt)
CA (1) CA2709032C (pt)
ES (1) ES2599927T3 (pt)
IL (1) IL206100A (pt)
MX (1) MX2010006659A (pt)
WO (1) WO2009080542A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010011306A (es) 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
CN102112442B (zh) * 2008-08-07 2014-12-10 弗·哈夫曼-拉罗切有限公司 制备大环的方法
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CN105001302A (zh) * 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
WO2011038283A1 (en) * 2009-09-28 2011-03-31 Hoffmann-La Roche Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
AU2011224558B2 (en) * 2010-03-10 2014-02-27 Abbvie Ireland Unlimited Company Solid compositions
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US20140100364A1 (en) 2012-10-08 2014-04-10 Abbvie Inc. Compounds Useful For Making HCV Protease Inhibitors
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN109280074A (zh) * 2017-07-20 2019-01-29 歌礼药业（浙江）有限公司 丹诺瑞韦钠晶体及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831108A (en) * 1995-08-03 1998-11-03 California Institute Of Technology High metathesis activity ruthenium and osmium metal carbene complexes
US7683180B2 (en) * 2001-04-16 2010-03-23 California Institute Of Technology Group 8 transition metal carbene complexes as enantionselective olefin metathesis catalysts
DE10335416A1 (de) * 2003-08-02 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Metathesekatalysatoren
HRP20130098T1 (hr) * 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
JP2008517896A (ja) * 2004-10-21 2008-05-29 ファイザー・インク Ｃ型肝炎ウイルスプロテアーゼの阻害剤並びにそれを用いた組成物及び治療
KR101294467B1 (ko) * 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
DE102006008520A1 (de) * 2006-02-22 2007-08-23 Lanxess Deutschland Gmbh Neue Katalysator-Systeme und deren Verwendung für Metathese-Reaktionen
PL379879A1 (pl) * 2006-06-07 2007-12-10 Umicore Ag & Co.Kg. Kompleksy rutenu i osmu, sposób ich wytwarzania oraz ich zastosowanie jako (pre)katalizatorów reakcji metatezy
WO2008086161A1 (en) 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors

Also Published As

Publication number Publication date
IL206100A (en) 2015-09-24
WO2009080542A1 (en) 2009-07-02
AU2008340430B2 (en) 2013-01-24
JP2011508729A (ja) 2011-03-17
CA2709032A1 (en) 2009-07-02
CN101903391A (zh) 2010-12-01
EP2225249A1 (en) 2010-09-08
AU2008340430A1 (en) 2009-07-02
ES2599927T3 (es) 2017-02-06
CN101903391B (zh) 2013-04-03
JP5439384B2 (ja) 2014-03-12
EP2225249B1 (en) 2016-08-03
US20090163706A1 (en) 2009-06-25
KR101629523B1 (ko) 2016-06-10
US7910728B2 (en) 2011-03-22
CA2709032C (en) 2016-02-23
KR20100106411A (ko) 2010-10-01
IL206100A0 (en) 2010-11-30
MX2010006659A (es) 2010-07-05

Similar Documents

Publication Publication Date Title
BRPI0820733A2 (pt) Processo para a preparação de macrociclo
BRPI0916609A2 (pt) Processo para a preparação de um macrociclo
BRPI0813284A2 (pt) Processos para a preparação de pirazóis
BRPI0812422A2 (pt) Processo de preparação de um aldeído hidroxiaromático
BRPI0816911A2 (pt) Processo para preparação de 4-aminobut-2-enolidas
BRPI0810842A2 (pt) Processo para a carbonilação de dimetil éter
BRPI0810817A2 (pt) Processo para a carbonilação de dimetil éter
BRPI0810067A2 (pt) Processo para a preparação de capecitabina
BRPI0721666A2 (pt) Processo para preparação de um compósito moldado reforçado
BRPI0815784A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0812304A2 (pt) Processo para a produção de p4o6
BRPI0810850A2 (pt) Processo para carbonilação de dimetil éter
BRPI0810846A2 (pt) Processo para carbonilção de dimetil éter
BRPI0811644A2 (pt) Processo para a produção de pirazóis
BRPI0809652A2 (pt) Processo melhorado para a síntese de solifenacina
BRPI0915572A2 (pt) processo para a fabricação de epicloroidrina
BRPI0914674A2 (pt) processo para preparação de um pó
BRPI0909393A2 (pt) processo para a preparação de polibutadieno
BRPI0813960A2 (pt) Processo para produção de biarilas
BRPI0815971A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0912558A2 (pt) Processo para a preparação de amidas
BRPI0921420A2 (pt) processo para preparar compostos
BRPI0808031A2 (pt) Processo para a preparação de di-n-butil tereftalato
BRPI0912202A2 (pt) processo para a preparação de um painel
BRPI0816237A2 (pt) Processo de ciclopropanação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.